Engineering of therapeutic proteins production in Escherichia coli

Current Pharmaceutical Biotechnology

Volumn 12, Issue 2, 2011, Pages 268-274

  Kamionka, Mariusz ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Biopharmaceuticals; Drug development; Protein drugs; Protein engineering; Protein expression; Therapeutic proteins

Indexed keywords

ALBINTERFERON ALPHA2B; BIOVITRUM; CONSENSUS INTERFERON; DEOXYRIBONUCLEASE I; DISULFIDE; GROWTH HORMONE; HUMAN INSULIN; INSULIN; INSULIN LISPRO; INTERFERON BETA SERINE; INTERLEUKIN 2; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PALIFERMIN; PROINSULIN; RECOMBINANT BETA INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HUMAN INSULIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; ESCHERICHIA COLI; GENE FUSION; GENE MUTATION; GENETIC ENGINEERING; GLYCOSYLATION; MELANOMA; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PROCESSING;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 79551646745     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794295693     Document Type: Article

References (42)

1. Johnson, I. S. Human insulin from recombinant DNA technology. Science, 1983, 219, (4585), 632-637.
2. Walsh, G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol., 2006, 24(7), 769-776.
3. Roifman, C. M.; Mills, G. B.; Chu, M.; Gelfand, E. W. Functional comparison of recombinant interleukin 2 (IL-2) with IL-2- containing preparations derived from cultured cells. Cell Immunol., 1985, 95(1), 146-156.
4. Crommelin, D. J. A.; Sindelar, R. D.; Meibohm, B. Pharmaceutical Biotechnology; 3rd ed.; Informa Healthcare: New York, 2008.
5. Narhi, L. O.; Arakawa, T.; Aoki, K.; Wen, J.; Elliott, S.; Boone, T.; Cheetham, J. Asn to Lys mutations at three sites which are Nglycosylated in the mammalian protein decrease the aggregation of Escherichia coli-derived erythropoietin. Protein Eng., 2001, 14(2), 135-140.
6. Macmillan, D.; Bill, R. M.; Sage, K. A.; Fern, D.; Flitsch, S. L. Selective in vitro glycosylation of recombinant proteins: semisynthesis of novel homogeneous glycoforms of human erythropoietin. Chem. Biol., 2001, 8(2), 133-145.
7. Zundorf, I.; Dingermann, T. From cattle, swine, and horse insulin to human insulin: the biotechnology and genetic technology of insulin production. Pharm. Unserer Zeit., 2001, 30(1), 27-32.
8. de Oliveira, J. E.; Soares, C. R.; Peroni, C. N.; Gimbo, E.; Camargo, I. M.; Morganti, L.; Bellini, M. H.; Affonso, R.; Arkaten, R. R.; Bartolini, P.; Ribela, M. T. High-yield purification of biosynthetic human growth hormone secreted in Escherichia coli periplasmic space. J. Chromatogr. A, 1999, 852(2), 441-450.
9. Winter, J.; Neubauer, P.; Glockshuber, R.; Rudolph, R., Increased production of human proinsulin in the periplasmic space of Escherichia coli by fusion to DsbA. J. Biotechnol., 2001, 84(2), 175-185.
10. Doyle, M. V.; Lee, M. T.; Fong, S. Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2. J. Biol. Response Mod., 1985, 4(1), 96-109.
11. O'Rourke, E. C.; Drummond, R. J.; Creasey, A. A. Binding of 125I-labeled recombinant beta interferon (IFN-beta Ser17) to human cells. Mol. Cell Biol., 1984, 4(12), 2745-2749.
12. Hsu, E.; Osslund, T.; Nybo, R.; Chen, B. L.; Kenney, W. C.; Morris, C. F.; Arakawa, T.; Narhi, L. O. Enhanced stability of recombinant keratinocyte growth factor by mutagenesis. Protein Eng. Des. Sel., 2006, 19(4), 147-153.
13. Howey, D. C.; Bowsher, R. R.; Brunelle, R. L.; Woodworth, J. R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes, 1994, 43(3), 396-402.
14. Brange, J. The new era of biotech insulin analogues. Diabetologia, 1997, 40 (Suppl 2), S48-S53.
15. Brange, J.; Ribel, U.; Hansen, J. F.; Dodson, G.; Hansen, M. T.; Havelund, S.; Melberg, S. G.; Norris, F.; Norris, K.; Snel, L. Monomeric insulins obtained by protein engineering and their medical implications. Nature, 1988, 333(6174), 679-682.
16. Bolli, G. B.; Owens, D. R. Insulin glargine. Lancet, 2000, 356(9228), 443-445.
17. Havelund, S.; Plum, A.; Ribel, U.; Jonassen, I.; Volund, A.; Markussen, J.; Kurtzhals, P. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res., 2004, 21(8), 1498-1504.
18. Pan, C. Q.; Lazarus, R. A. Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism. Biochemistry, 1997, 36(22), 6624-6632.
19. Alton, K.; Stabinsky, Y.; Richards, R. In: Production, Characterization and Biological Effects of Recombinant DNA Derived Human IFN-α and IFN-γ Analogs; The Biology of the Interferon System, De Maeyer, E.; Schellekens, H., Eds.; Elsevier Science Publishers: Amsterdam, 1983; pp 119-128.
20. Blatt, L. M.; Davis, J. M.; Klein, S. B.; Taylor, M. W. The biologic activity and molecular characterization of a novel synthetic interferon- alpha species, consensus interferon. J. Interferon Cytokine Res., 1996, 16(7), 489-499.
21. Varki, A.; Cummings, R. D.; Esko, J. D.; Freeze, H. H.; Stanley, P.; Bertozzi, C. R.; Hart, G. W.; Etzler, M. E. Essentials of Glycobiology; 2nd ed.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 2008.
22. Rosenberg, A. S. Effects of protein aggregates: an immunologic perspective. AAPS J., 2006, 8(3), E501-E507.
23. Dissing-Olesen, L.; Thaysen-Andersen, M.; Meldgaard, M.; Hojrup, P.; Finsen, B. The function of the human interferon-beta 1a glycan determined in vivo. J. Pharmacol. Exp. Ther., 2008, 326(1), 338-347.
24. Elliott, S.; Lorenzini, T.; Asher, S.; Aoki, K.; Brankow, D.; Buck, L.; Busse, L.; Chang, D.; Fuller, J.; Grant, J.; Hernday, N.; Hokum, M.; Hu, S.; Knudten, A.; Levin, N.; Komorowski, R.; Martin, F.; Navarro, R.; Osslund, T.; Rogers, G.; Rogers, N.; Trail, G.; Egrie, J. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol., 2003, 21(4), 414-421.
25. Egrie, J. C.; Dwyer, E.; Browne, J. K.; Hitz, A.; Lykos, M. A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol., 2003, 31(4), 290-299.
26. Goeddel, D. V.; Kleid, D. G.; Bolivar, F.; Heyneker, H. L.; Yansura, D. G.; Crea, R.; Hirose, T.; Kraszewski, A.; Itakura, K.; Riggs, A. D. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc. Natl. Acad. Sci. USA, 1979, 76(1), 106-110.
27. Trivedi, M. V.; Laurence, J. S.; Siahaan, T. J. The role of thiols and disulfides on protein stability. Curr. Protein Pept. Sci., 2009, 10(6), 614-625.
28. Blijlevens, N.; Sonis, S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapyinduced mucositis. Ann. Oncol., 2007, 18(5), 817-826.
29. Subramanian, G. M.; Fiscella, M.; Lamouse-Smith, A.; Zeuzem, S.; McHutchison, J. G. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat. Biotechnol., 2007, 25(12), 1411-1419.
30. Balan, V. Albumin-interferon-α in the treatment of chronic hepatitis C. Future Virol., 2006, 1, 269-278.
31. Duttaroy, A.; Kanakaraj, P.; Osborn, B. L.; Schneider, H.; Pickeral, O. K.; Chen, C.; Zhang, G.; Kaithamana, S.; Singh, M.; Schulingkamp, R.; Crossan, D.; Bock, J.; Kaufman, T. E.; Reavey, P.; Carey-Barber, M.; Krishnan, S. R.; Garcia, A.; Murphy, K.; Siskind, J. K.; McLean, M. A.; Cheng, S.; Ruben, S.; Birse, C. E.; Blondel, O. Development of a long-acting insulin analog using albumin fusion technology. Diabetes, 2005, 54(1), 251-258.
32. Osborn, B. L.; Sekut, L.; Corcoran, M.; Poortman, C.; Sturm, B.; Chen, G.; Mather, D.; Lin, H. L.; Parry, T. J. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol., 2002, 456(1-3), 149-158.
33. Melder, R. J.; Osborn, B. L.; Riccobene, T.; Kanakaraj, P.; Wei, P.; Chen, G.; Stolow, D.; Halpern, W. G.; Migone, T. S.; Wang, Q.; Grzegorzewski, K. J.; Gallant, G. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol. Immunother., 2005, 54(6), 535-547.
34. Wang, W.; Ou, Y.; Shi, Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm. Res., 2004, 21(11), 2105-2111.
35. Gomme, P. T.; McCann, K. B.; Bertolini, J. Transferrin: structure, function and potential therapeutic actions. Drug Discov. Today, 2005, 10(4), 267-273.
36. Bai, Y.; Ann, D. K.; Shen, W. C. Recombinant granulocyte colonystimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc, Natl, Acad, Sci, USA, 2005, 102(20), 7292-7296.
37. Amet, N.; Wang, W.; Shen, W. C. Human growth hormonetransferrin fusion protein for oral delivery in hypophysectomized rats. J. Control Release, 2010, 141(2), 177-182.
38. Zuppinger, K.; Aebi, C.; Fankhauser, S.; Herz, G.; Zurbrugg, R. P.; Schopfer, K.; Neri, T. M. Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus. Diabetologia, 1987, 30(12), 912-915.
39. Morihara, K.; Oka, T.; Tsuzuki, H. Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulin. Nature, 1979, 280(5721), 412-413.
40. Souza, L. M.; Boone, T. C.; Gabrilove, J.; Lai, P. H.; Zsebo, K. M.; Murdock, D. C.; Chazin, V. R.; Bruszewski, J.; Lu, H.; Chen, K. K. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science, 1986, 232, (4746), 61-65.
41. Herbert, K. E.; Prince, H. M.; Ritchie, D. S.; Seymour, J. F. The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution. Expert Opin. Biol. Ther., 2010, 10, 113-125.
42. Kalliolias, G. D.; Liossis, S. N. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin. Investig. Drugs, 2008, 17(3), 349-359.